Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Small-molecule ferroptosis inducers and sensitizers in anticancer drug discovery: medicinal chemistry, structure-activity relationships, and translational perspectives.

Created on 25 Oct 2026

Authors

Aashik Malik, Md Arif Naseer, Mayank Yadav, Zulphikar Ali, Jai Parkash Kadian

Published in

Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents. Oct 24, 2026. Epub Oct 24, 2026.

Abstract

Ferroptosis, an iron-dependent form of regulated cell death driven by phospholipid peroxidation, proceeds independently of caspase activation and can remain effective in apoptosis-resistant and mesenchymal-like tumor populations, providing a pharmacologically addressable route around treatment resistance. Its regulation by enzymes, transporters and metabolic pathways, including glutathione peroxidase 4 (GPX4), the cystine/glutamate antiporter system xc⁻, ferroptosis suppressor protein 1 (FSP1), mitochondrial dihydroorotate dehydrogenase (DHODH), and iron and lipid metabolism, has created multiple starting points for small-molecule design. Unlike prior target-by-target surveys, this review cross-examines structure-activity relationships across these target classes to distinguish transferable design principles from mechanism-specific effects, and chemical probes from pharmacologically viable leads. Cross-target analysis shows that no single SAR pattern governs ferroptosis induction: scaffold requirements are target-dependent, linker length and rigidity produce mechanism-dependent effects, and electrophilic warheads require calibrated rather than maximal reactivity. Substituent modifications that improve one chemotype do not reliably transfer to another, while hybrid and multi-target compounds require evidence for target-specific contributions to activity. Translational evaluation reveals a recurring gap between cellular potency and the solubility, metabolic stability, systemic exposure, in vivo efficacy and tolerability required for development. Most compounds remain chemical probes, with PK/ADMET characterization, therapeutic-window data, off-target control and validated biomarkers for patient selection frequently lacking. Progress will therefore depend less on increasing ferroptotic potency than on converting active chemotypes into target-selective, pharmacokinetically viable and tolerable agents for biomarker-defined patient populations. Graphical abstract illustrating key druggable targets in ferroptosis, including GPX4, System Xc⁻, FSP1, DHODH, and iron/lipid metabolism, and the drug-development pathway from chemical probe discovery and SAR optimization to lead development, evaluation of translational limitations, and biomarker-guided translation.

PMID:
42925327
Bibliographic data and abstract were imported from PubMed on 25 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 24
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement